Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy

Federica Palorini, Tiziana Rancati, Cesare Cozzarini, Ilaria Improta, Viviana Carillo, Barbara Avuzzi, Valeria Casanova Borca, Andrea Botti, Claudio Degli Esposti, Pierfrancesco Franco, Elisabetta Garibaldi, Giuseppe Girelli, Cinzia Iotti, Angelo Maggio, Marcella Palombarini, Alessio Pierelli, Emanuele Pignoli, Vittorio Vavassori, Riccardo Valdagni, Claudio Fiorino

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose/objective Prospectively assessing clinical/dosimetry factors affecting the acute worsening of urinary functionality after radiotherapy for prostate cancer. Material/methods DUE01 population was considered, including patients treated with conventional or moderate hypo-fractionation (2.2-2.7 Gy/fr). Relevant clinical factors were collected, urinary symptoms were self-reported through the International Prostate Symptom Score (IPSS) before and at the end of radiotherapy; while absolute weekly dose-surface histograms (DSHw) were chosen as dosimetry descriptors. An IPSS increase of at least 10 and 15 points (ΔIPSS ≥ 10 and ΔIPSS ≥ 15) were chosen as endpoints. Patients with baseline IPSS > 20 were excluded. Relevant factors were chosen through a bootstrap-based in silico methodology. Results Complete information was available for 380 patients: 77/380 (20%) and 28/380 (7%) with ΔIPSS ≥ 10 and ΔIPSS ≥ 15, respectively. Neoadjuvant hormone was protective (OR = 0.49 and 0.69). DSHw at 8.5 Gy/week and 12 Gy/week were risk factors, with additional risk for patients who use cardiovascular drugs and anti-hypercholesterolemia drugs. In the hypo-fractionated subgroup (n = 209) the role of cardiovascular drugs (OR = 2.16) for ΔIPSS ≥ 10 and anti-hypercholesterolemia drugs (OR = 2.80) for ΔIPSS ≥ 15, together with DSHw (10 Gy/week and 12.5 Gy/week, respectively), was confirmed. Conclusion Current study shows a dose-surface/volume effect for acute large worsening of urinary functionality; several clinical variables largely impact the risk and especially all the factors related with vascular diseases.

Original languageEnglish
Pages (from-to)92-98
Number of pages7
JournalRadiotherapy and Oncology
Volume118
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Prostate
Prostatic Neoplasms
Radiotherapy
Cardiovascular Agents
Therapeutics
Hypercholesterolemia
Vascular Diseases
Pharmaceutical Preparations
Computer Simulation
Hormones
Population

Keywords

  • Dose-volume effects
  • Prostate cancer
  • Radiotherapy
  • Urinary toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy. / Palorini, Federica; Rancati, Tiziana; Cozzarini, Cesare; Improta, Ilaria; Carillo, Viviana; Avuzzi, Barbara; Casanova Borca, Valeria; Botti, Andrea; Degli Esposti, Claudio; Franco, Pierfrancesco; Garibaldi, Elisabetta; Girelli, Giuseppe; Iotti, Cinzia; Maggio, Angelo; Palombarini, Marcella; Pierelli, Alessio; Pignoli, Emanuele; Vavassori, Vittorio; Valdagni, Riccardo; Fiorino, Claudio.

In: Radiotherapy and Oncology, Vol. 118, No. 1, 01.01.2016, p. 92-98.

Research output: Contribution to journalArticle

Palorini, F, Rancati, T, Cozzarini, C, Improta, I, Carillo, V, Avuzzi, B, Casanova Borca, V, Botti, A, Degli Esposti, C, Franco, P, Garibaldi, E, Girelli, G, Iotti, C, Maggio, A, Palombarini, M, Pierelli, A, Pignoli, E, Vavassori, V, Valdagni, R & Fiorino, C 2016, 'Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy', Radiotherapy and Oncology, vol. 118, no. 1, pp. 92-98. https://doi.org/10.1016/j.radonc.2015.11.036
Palorini, Federica ; Rancati, Tiziana ; Cozzarini, Cesare ; Improta, Ilaria ; Carillo, Viviana ; Avuzzi, Barbara ; Casanova Borca, Valeria ; Botti, Andrea ; Degli Esposti, Claudio ; Franco, Pierfrancesco ; Garibaldi, Elisabetta ; Girelli, Giuseppe ; Iotti, Cinzia ; Maggio, Angelo ; Palombarini, Marcella ; Pierelli, Alessio ; Pignoli, Emanuele ; Vavassori, Vittorio ; Valdagni, Riccardo ; Fiorino, Claudio. / Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy. In: Radiotherapy and Oncology. 2016 ; Vol. 118, No. 1. pp. 92-98.
@article{b90ab84bd77f42b3a08da4f247b4c499,
title = "Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy",
abstract = "Purpose/objective Prospectively assessing clinical/dosimetry factors affecting the acute worsening of urinary functionality after radiotherapy for prostate cancer. Material/methods DUE01 population was considered, including patients treated with conventional or moderate hypo-fractionation (2.2-2.7 Gy/fr). Relevant clinical factors were collected, urinary symptoms were self-reported through the International Prostate Symptom Score (IPSS) before and at the end of radiotherapy; while absolute weekly dose-surface histograms (DSHw) were chosen as dosimetry descriptors. An IPSS increase of at least 10 and 15 points (ΔIPSS ≥ 10 and ΔIPSS ≥ 15) were chosen as endpoints. Patients with baseline IPSS > 20 were excluded. Relevant factors were chosen through a bootstrap-based in silico methodology. Results Complete information was available for 380 patients: 77/380 (20{\%}) and 28/380 (7{\%}) with ΔIPSS ≥ 10 and ΔIPSS ≥ 15, respectively. Neoadjuvant hormone was protective (OR = 0.49 and 0.69). DSHw at 8.5 Gy/week and 12 Gy/week were risk factors, with additional risk for patients who use cardiovascular drugs and anti-hypercholesterolemia drugs. In the hypo-fractionated subgroup (n = 209) the role of cardiovascular drugs (OR = 2.16) for ΔIPSS ≥ 10 and anti-hypercholesterolemia drugs (OR = 2.80) for ΔIPSS ≥ 15, together with DSHw (10 Gy/week and 12.5 Gy/week, respectively), was confirmed. Conclusion Current study shows a dose-surface/volume effect for acute large worsening of urinary functionality; several clinical variables largely impact the risk and especially all the factors related with vascular diseases.",
keywords = "Dose-volume effects, Prostate cancer, Radiotherapy, Urinary toxicity",
author = "Federica Palorini and Tiziana Rancati and Cesare Cozzarini and Ilaria Improta and Viviana Carillo and Barbara Avuzzi and {Casanova Borca}, Valeria and Andrea Botti and {Degli Esposti}, Claudio and Pierfrancesco Franco and Elisabetta Garibaldi and Giuseppe Girelli and Cinzia Iotti and Angelo Maggio and Marcella Palombarini and Alessio Pierelli and Emanuele Pignoli and Vittorio Vavassori and Riccardo Valdagni and Claudio Fiorino",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.radonc.2015.11.036",
language = "English",
volume = "118",
pages = "92--98",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy

AU - Palorini, Federica

AU - Rancati, Tiziana

AU - Cozzarini, Cesare

AU - Improta, Ilaria

AU - Carillo, Viviana

AU - Avuzzi, Barbara

AU - Casanova Borca, Valeria

AU - Botti, Andrea

AU - Degli Esposti, Claudio

AU - Franco, Pierfrancesco

AU - Garibaldi, Elisabetta

AU - Girelli, Giuseppe

AU - Iotti, Cinzia

AU - Maggio, Angelo

AU - Palombarini, Marcella

AU - Pierelli, Alessio

AU - Pignoli, Emanuele

AU - Vavassori, Vittorio

AU - Valdagni, Riccardo

AU - Fiorino, Claudio

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose/objective Prospectively assessing clinical/dosimetry factors affecting the acute worsening of urinary functionality after radiotherapy for prostate cancer. Material/methods DUE01 population was considered, including patients treated with conventional or moderate hypo-fractionation (2.2-2.7 Gy/fr). Relevant clinical factors were collected, urinary symptoms were self-reported through the International Prostate Symptom Score (IPSS) before and at the end of radiotherapy; while absolute weekly dose-surface histograms (DSHw) were chosen as dosimetry descriptors. An IPSS increase of at least 10 and 15 points (ΔIPSS ≥ 10 and ΔIPSS ≥ 15) were chosen as endpoints. Patients with baseline IPSS > 20 were excluded. Relevant factors were chosen through a bootstrap-based in silico methodology. Results Complete information was available for 380 patients: 77/380 (20%) and 28/380 (7%) with ΔIPSS ≥ 10 and ΔIPSS ≥ 15, respectively. Neoadjuvant hormone was protective (OR = 0.49 and 0.69). DSHw at 8.5 Gy/week and 12 Gy/week were risk factors, with additional risk for patients who use cardiovascular drugs and anti-hypercholesterolemia drugs. In the hypo-fractionated subgroup (n = 209) the role of cardiovascular drugs (OR = 2.16) for ΔIPSS ≥ 10 and anti-hypercholesterolemia drugs (OR = 2.80) for ΔIPSS ≥ 15, together with DSHw (10 Gy/week and 12.5 Gy/week, respectively), was confirmed. Conclusion Current study shows a dose-surface/volume effect for acute large worsening of urinary functionality; several clinical variables largely impact the risk and especially all the factors related with vascular diseases.

AB - Purpose/objective Prospectively assessing clinical/dosimetry factors affecting the acute worsening of urinary functionality after radiotherapy for prostate cancer. Material/methods DUE01 population was considered, including patients treated with conventional or moderate hypo-fractionation (2.2-2.7 Gy/fr). Relevant clinical factors were collected, urinary symptoms were self-reported through the International Prostate Symptom Score (IPSS) before and at the end of radiotherapy; while absolute weekly dose-surface histograms (DSHw) were chosen as dosimetry descriptors. An IPSS increase of at least 10 and 15 points (ΔIPSS ≥ 10 and ΔIPSS ≥ 15) were chosen as endpoints. Patients with baseline IPSS > 20 were excluded. Relevant factors were chosen through a bootstrap-based in silico methodology. Results Complete information was available for 380 patients: 77/380 (20%) and 28/380 (7%) with ΔIPSS ≥ 10 and ΔIPSS ≥ 15, respectively. Neoadjuvant hormone was protective (OR = 0.49 and 0.69). DSHw at 8.5 Gy/week and 12 Gy/week were risk factors, with additional risk for patients who use cardiovascular drugs and anti-hypercholesterolemia drugs. In the hypo-fractionated subgroup (n = 209) the role of cardiovascular drugs (OR = 2.16) for ΔIPSS ≥ 10 and anti-hypercholesterolemia drugs (OR = 2.80) for ΔIPSS ≥ 15, together with DSHw (10 Gy/week and 12.5 Gy/week, respectively), was confirmed. Conclusion Current study shows a dose-surface/volume effect for acute large worsening of urinary functionality; several clinical variables largely impact the risk and especially all the factors related with vascular diseases.

KW - Dose-volume effects

KW - Prostate cancer

KW - Radiotherapy

KW - Urinary toxicity

UR - http://www.scopus.com/inward/record.url?scp=84959533025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959533025&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2015.11.036

DO - 10.1016/j.radonc.2015.11.036

M3 - Article

AN - SCOPUS:84959533025

VL - 118

SP - 92

EP - 98

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 1

ER -